Acquisition leverage Claret Medical has been acquired by Boston Scientific, presenting an opportunity to leverage the parent company’s extensive sales network, distribution channels, and cross-selling potential to expand the Sentinel cerebral protection system adoption.

Regulatory footprint With Sentinel being the first FDA-cleared cerebral protection device for TAVR and strong European market leadership, there is potential to expand regulatory and reimbursement discussions, targeting US hospital systems and international clinics integrating TAVR programs.

Clinical impact The device demonstrated a 63% reduction in peri-procedural strokes in trials, a compelling clinical value proposition for health systems focused on stroke reduction and patient outcomes, enabling value-based selling and case studies.

Financial tiering Current revenue is under $1M, indicating significant upside for scalable adoption through Boston Scientific’s broader portfolio and leveraging existing procurement contracts, group purchasing organizations, and hospital partnerships.

Market consolidation Dominant European market share and being a pioneer in cerebral protection position Sentinel as a differentiator within the broader cardiovascular device arena, providing cross-sell opportunities to related TAVR and neurovascular product lines.